Ali Mohamed Hammad

Ali Mohamed Hammad

Auto-generated profile, based on publicly available information

Ali Mohamed Hammad

Medical Research Group of Egypt, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
MGMohamed Gadelkarim
Mohamed Gadelkarim
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
EGEsraa Ghanem
Esraa Ghanem
AHAli Mohamed Hamaad
Ali Mohamed Hamaad
ASAnas M. Saad
Anas M. Saad
Mohamed Abdel-DaimMohamed Abdel-Daim
Mohamed Abdel-Daim

5 April 2018 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
Mohannad EledreesiMohannad Eledreesi
Mohannad Eledreesi
TDThomas M. Drake
Thomas M. Drake
JCJulian Camilleri-Brennan
Julian Camilleri-Brennan
STStephen Tabiri
Stephen Tabiri
SFStuart J. Fergusson
Stuart J. Fergusson
EEEugenio Grasset Escobar
Eugenio Grasset Escobar
Background: Appendicitis is the most common abdominal surgical emergency worldwide. Differences between high- and low-income settings in the availability of laparoscopic appendectomy, alternative management choices, and outcomes are poorly described. The aim was to identify variation in surgical management and outcomes of appendicitis within low-, middle-, and high-Human Development Index (HDI) countries worldwide. Methods: This is a multicenter, international prospective cohort study. Consecutive sampling of patients undergoing emergency appendectomy over 6 months was conducted. Follow-up lasted 30 days. Results: 4546 patients from 52 countries underwent appendectomy (2499 high-, 1540 middle-, and 507 low-HDI groups). Surgical site infection (SSI) rates were higher in low-HDI (OR 2.57, 95% CI 1.33–4.99, p = 0.005) but not middle-HDI countries (OR 1.38, 95% CI 0.76–2.52, p = 0.291), compared with high-HDI countries after adjustment. A laparoscopic approach was common in high-HDI countries (1693/2499, 67.7%), but infrequent in low-HDI (41/507, 8.1%) and middle-HDI (132/1540, 8.6%) groups. After accounting for case-mix, laparoscopy was still associated with fewer overall complications (OR 0.55, 95% CI 0.42–0.71, p < 0.001) and SSIs (OR 0.22, 95% CI 0.14–0.33, p < 0.001). In propensity-score matched groups within low-/middle-HDI countries, laparoscopy was still associated with fewer overall complications (OR 0.23 95% CI 0.11–0.44) and SSI (OR 0.21 95% CI 0.09–0.45). Conclusion: A laparoscopic approach is associated with better outcomes and availability appears to differ by country HDI. Despite the profound clinical, operational, and financial barriers to its widespread introduction, laparoscopy could significantly improve outcomes for patients in low-resource environments. Trial registration: NCT02179112.

26 April 2018 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
AAAbdelrahman Ibrahim Abushouk
Abdelrahman Ibrahim Abushouk
Ahmed NegidaAhmed Negida
Ahmed Negida
RERasha Abdelsalam Elshenawy
Rasha Abdelsalam Elshenawy
HZHossam Zein
Hossam Zein
AHAli M. Hammad
Ali M. Hammad
WMWael M.Y. Mohamed
Wael M.Y. Mohamed
Parkinson's disease (PD) is the most prevalent movement disorder in the world. The major pathological hallmarks of PD are death of dopaminergic neurons and the formation of Lewy bodies. At the moment, there is no cure for PD; current treatments are symptomatic. Investigators are searching for neuroprotective agents and disease modifying strategies to slow the progress of neurodegeneration. However, due to lack of data about the main pathological sequence of PD, many drug targets failed to provide neuroprotective effects in human trials. Recent evidence suggests the involvement of C-Abelson (c-Abl) tyrosine kinase enzyme in the pathogenesis of PD. Through parkin inactivation, alpha synuclein aggregation, and impaired autophagy of toxic elements. Experimental studies showed that (1) c-Abl activation is involved in neurodegeneration and (2) c-Abl inhibition shows neuroprotective effects and prevents dopaminergic neuronal' death. Current evidence from experimental studies and the first in-human trial shows that c-Abl inhibition holds the promise for neuroprotection against PD and therefore, justifies the movement towards larger clinical trials. In this review article, we discussed the role of c-Abl in PD pathogenesis and the findings of preclinical experiments and the first in-human trial. In addition, based on lessons from the last decade and current preclinical evidence, we provide recommendations for future research in this area.

1 April 2019 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
WRWafaa Rashed
Wafaa Rashed
AHAli M. Hammad
Ali M. Hammad
ASAnas M. Saad
Anas M. Saad
KSKyrillus S. Shohdy
Kyrillus S. Shohdy

1 January 2018 in Toxicology Reports
Verified
Journal Article
Open access
DJDina Johar
Dina Johar
AMAhmed Maher
Ahmed Maher
OAOmnia Aboelmagd
Omnia Aboelmagd
AHAli Hammad
Ali Hammad
MMMahmoud Morsi
Mahmoud Morsi
SZSamy Zaky
Samy Zaky
The importance of whole-food antioxidants in terms of promoting antioxidant recycling in the body in complex human diseases is not fully understood. We aim to discuss the benefits of whole-food antioxidants in ameliorating the diabetic complications in vivo and to address the effect of germination versus heat processing or drying on the potential therapeutic effect of whole grains and legumes. We studied the antioxidant status of alloxan-diabetic (AD) male Spargue Dawley rats, injected intraperitoneally with alloxan dose of 150 mg/kg body weight, and fed on experimental diets based on the flour of soybean, broadbean and whole-wheat for five weeks. Diabetes-induced oxidative stress in liver was manifested by significant increase in hepatic malondialdehyde (MDA), erythrocytes superoxide dismutase (eSOD) and plasma alpha-tocopherol (α-T) levels, reduction in hepatic glutathione (GSH) levels and catalase (CAT) activity. Consumption of soybean and whole-wheat both had beneficial effects on the oxidative status of AD rats more than broadbean. Feeding dried wheat was effective in improving MDA, GSH and α-T levels. Soybeans and wheat lowered triacylglycerols (TAGs) and tended to lower total cholesterol. Germination enhanced the effect of soybeans on TAGs and in the case of soy and wheat enhanced the effect on total cholesterol. Whole foods containing naturally occurring phytochemicals and antioxidant vitamins such as legumes and whole grains are recommended, alongside medication, for controlling hyperglycaemia, blood lipids and oxidative status in diabetes.

1 July 2016 in Antiviral Therapy
Verified
Journal Article
Closed access
HAHussien Ahmed
Hussien Ahmed
AEAhmed Elgebaly
Ahmed Elgebaly
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
AHAli Mohamed Hammad
Ali Mohamed Hammad
AAAttia Attia
Attia Attia
Ahmed NegidaAhmed Negida
Ahmed Negida
Background: Ledipasvir and sofosbuvir are new direct-acting antiviral agents for patients with HCV infection. Ledipasvir inhibits the HCV non-structural 5A protein, while sofosbuvir is a nucleotide polymerase inhibitor. Many studies have evaluated the safety and efficacy of ledipasvir and sofosbuvir combination with and without ribavirin for patients with chronic HCV genotype-1. Methods: A computer literature search of PubMed, SCOPUS, Web of Knowledge and Cochrane CENTRAL has been conducted. Studies were screened for eligibility and data were extracted. Sustained virological response (SVR) rate and commonly reported adverse events were pooled as risk ratio (RR) using Review Manager version 5.3 for windows and OpenMeta (Analyst) software. Results: Eight randomized controlled trials ( n=1,892) were pooled in the final analysis. A 12-week ledipasvir and sofosbuvir regimen achieved SVR in 97.5% and 89% of non-cirrhotic and cirrhotic patients, respectively. A 24-week ledipasvir and sofosbuvir regimen achieved SVR in 99.6% and 92.6% in non-cirrhotic and cirrhotic patients, respectively. When ribavirin was added to the treatment regiment, the SVR did not differ significantly in either of the treatment regimens (12-week SVR: 93.9% versus 96.7%, RR=0.97, P=0.19 and 24-week SVR: 94.8% versus 97.2%, RR=0.98, P=0.24). Conclusions: The combination of sofosbuvir and ledipasvir achieved high SVR rates (>90%) in both cirrhotic and non-cirrhotic patients with HCV genotype-1. The addition of ribavirin to this regimen did not signifcantly increase the SVR rates.